Results 21 to 30 of about 829 (260)

Sustained Therapeutic Efficacy of Intravenous Plasminogen Concentrate in Pediatric Patients With Type 1 Plasminogen Deficiency: An Analysis of Dosing Parameters and Clinical Outcomes

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Type 1 plasminogen deficiency (PLGD‐1) is an ultra‐rare autosomal recessive disorder caused by variants in the PLG gene and affects approximately 1.6 individuals per million. The condition is characterized by decreased plasminogen levels and impaired function, resulting in fibrin‐rich lesions on mucous membranes throughout the body.
Charles Nakar   +7 more
wiley   +1 more source

Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot   +6 more
wiley   +1 more source

Guidelines for Pediatric Radiotherapy Simulation: A Report From the Children's Oncology Group Radiation Oncology Discipline

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric radiation therapy presents unique challenges compared to adult treatments, including those of immobilization, potential need for sedation, and the critical importance of accurate, reproducible positioning. Additionally, heightened attention to imaging doses is necessary to minimize long‐term toxicity in survivors.
Parham Alaei   +17 more
wiley   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko   +19 more
wiley   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol   +6 more
wiley   +1 more source

Resistencia bacteriana a antibióticos en el Hospital San Juan de Dios, 1995-1999

open access: yesActa Médica Costarricense, 2001
Justificación: La resistencia a antibióticos por parte de bacterias patógenas es un grave problema mundial. Su control ha sido difícil pero deben hacerse todos los esfuerzos por realizarlo.
Ricardo Boza-Cordero   +1 more
doaj   +2 more sources

BMT4me En Español: Multisite Feasibility and Usability Testing of a Spanish‐Language mHealth Adherence Support App for Spanish‐Speaking Caregivers of Children After Hematopoietic Stem Cell Transplantation and Cancer Treatment

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Medication nonadherence during the first 100 days after pediatric hematopoietic stem cell transplantation (HSCT) and during oncology treatment increases risk for complications. BMT4me is a caregiver‐facing mobile health (mHealth) application providing medication reminders, symptom tracking, and note‐taking features to support ...
Micah A. Skeens   +4 more
wiley   +1 more source

Factores de riesgo para bacteriemias por enterobacterias productoras de betalactamasa de expectro extendido

open access: yesAnales de la Facultad de Medicina, 2018
Las bacteriemias por enterobacterias se presentan como un desafío terapéutico y diagnóstico, por su frecuencia, morbimortalidad y adquisición de mecanismos de resistencia.
Florencia Cristiano   +7 more
doaj  

Infecciones por enterobacterias productoras de betalactamasas de espectro extendido tras cirugía cardiaca: su impacto en la mortalidad

open access: yesRevista Colombiana de Cardiología, 2016
Introducción: Las enterobacterias productoras de betalactamasas de espectro extendido (EP BLEE) causan infecciones nosocomiales de modo creciente. Es controvertido si se asocian a peor pronóstico.
Francisco F. Rodríguez-Vidigal   +3 more
doaj   +1 more source

AVALIAÇÃO DO PERFIL DE RESISTÊNCIA DE ENTEROBACTÉRIAS PRODUTORAS DE AMPC NO HOSPITAL DE CLÍNICAS DE PORTO ALEGRE

open access: yesBrazilian Journal of Infectious Diseases, 2023
Introdução: A resistência bacteriana tem aumentado mundialmente pelo maior uso de antibióticos, terapias imunossupressoras e internações prolongadas, cenários frequentes após 2020, com a emergência da pandemia por Covid-19. Os gram-negativos, em especial
Ana Elize Barin   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy